Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 30

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 30
---
     55,000 
  
    Accrued consulting and
    professional services 
     87,099  
     941,600 

    $365,060  
    $1,913,175 

14

NOTE 7
– LEASES

As
of June 30, 2025 and December 31, 2024, the Company holds a five-year lease for laboratory and office space. The lease has escalating
contractual rent and variable rent components and the Company elected to separate the contractual and variable elements for valuing the
operating lease liability and right-to-use asset. The lease does not have any options for extension or expansion. The Company recorded
the following lease costs:

    For
    the three months ended June 30,  
    For the
    six months  ended  June 30,  
    For the
    period from February 14, 2024  through June 30,  
    For the
    period from January 1, 2024  through February 13, 

    2025  
    2024  
    2025  
    2024  
    2024 

    (Successor)  
    (Successor)  
    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Operating leases: 

    Operating lease cost 
    $229,331  
    $237,925  
    $458,662  
    $356,371  
    $110,885 
  
    Variable operating lease
    cost 
     224,874  
     174,349  
     412,604  
     264,504  
     84,401 
  
    Total lease cost 
    $454,205  
    $412,274  
    $871,266  
    $620,875  
    $195,286 

The
right-of-use asset, net for the operating lease was recorded in the consolidated balance sheets as follows:

    June 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Right-of-use
    assets, net 
    $1,072,950  
    $1,464,367 

The
oper